Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NUDT1 | P36639 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 5/20 | 0.32 |
| ▸ | MTOR | P42345 | 3/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 3/20 | 0.31 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.31 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16460561 | 0.94 | NUDT1 (0.35) | NUDT1PIK3CAMTORPIK3CBPIK3CD | |
| SCHEMBL16459883 | 0.92 | NUDT1 (0.33) | NUDT1PIK3CAMTORPIK3CBPIK3CD | |
| SCHEMBL16461137 | 0.91 | NUDT1 (0.32) | NUDT1PIK3CAMTOR | |
| SCHEMBL16476905 | 0.91 | NUDT1 (0.32) | NUDT1PIK3CAMTOR | |
| SCHEMBL16460039 | 0.91 | NUDT1 (0.32) | NUDT1PIK3CAMTORPIK3CBPIK3CD | |
| SCHEMBL16459945 | 0.90 | PIK3CA (0.33) | PIK3CAMTORPIK3CBPIK3CDPIK3CG | |
| SCHEMBL16460301 | 0.90 | NUDT1 (0.32) | NUDT1PIK3CAPIK3CBPIK3CDPIK3CG | |
| SCHEMBL16459641 | 0.89 | NUDT1 (0.32) | NUDT1PIK3CAMTOR | |
| SCHEMBL16476886 | 0.88 | MBOAT4 (0.32) | NUDT1PIK3CAMTOR | |
| SCHEMBL16459620 | 0.88 | PIK3CD (0.31) | PIK3CAMTORPIK3CBPIK3CDPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | claimed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2014-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140107100-A1 | Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture | MTOR, RICTOR, PIK3CA | NUDT1 3773/4885PIK3CA 3/4885MTOR 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.